Sage Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$1.1B
Lead Investor(s):J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC

Estimated Revenue & Financials

  • Sage Therapeutics's estimated annual revenue is currently $70.4M per year.(?)
  • Sage Therapeutics received $575.0M in venture funding in February 2018.
  • Sage Therapeutics's estimated revenue per employee is $155,000
  • Sage Therapeutics's total funding is $1.1B.

Employee Data

  • Sage Therapeutics has 454 Employees.(?)
  • Sage Therapeutics grew their employee count by -24% last year.
  • Sage Therapeutics currently has 18 job openings.

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.